SEATTLE, April 11, 2023 (GLOBE NEWSWIRE) — Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that dosing in the phase 1 clinical trial of CHK-336 in healthy volunteers has been voluntarily paused to allow a…Read More
Chinook Therapeutics Announces Voluntary Pause in Dosing of CHK336 in Ongoing Phase 1 Clinical Trial in Healthy Volunteers
